MT-7117 Formulation Code C, MT-7117 Placebo clinical trials

MT-7117-A-302 Study: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-Linked Protoporphyria

This study is testing a new medicine, MT-7117, for adults and teenagers with rare conditions called Erythropoietic Protoporphyria or X-Linked Protoporphyria (EPP/XLP). It looks at how well the medicine helps people spend more time in the sun without experiencing painful skin symptoms.